Drug Development: Allucent Expands Use of Medidata Clinical Cloud

What You Should Know:

– Medidata announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering. 

 – The agreement expands Allucent’s existing utilization of Medidata technologies. These include Rave EDC, eCOA, RTSM, and Rave Imaging, in support of critical areas of development, including oncology, rare and orphan indications, and cell and gene therapies. 

– As part of this agreement, Allucent’s team also achieved 100% Rave EDC certification, reinforcing their commitment to quality, and providing their clients with best-in-class technology.

What You Should Know:

– Medidata announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering. 

 – The agreement expands Allucent’s existing utilization of Medidata technologies. These include Rave EDC, eCOA, RTSM, and Rave Imaging, in support of critical areas of development, including oncology, rare and orphan indications, and cell and gene therapies. 

– As part of this agreement, Allucent’s team also achieved 100% Rave EDC certification, reinforcing their commitment to quality, and providing their clients with best-in-class technology.